Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locally Advanced or Metastatic Gastric Adenocarcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT05008783
What this trial is testing

AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Akeso 610
Testing effectiveness (Phase 2)WithdrawnNCT03704077
What this trial is testing

An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric CancerCancer of the StomachStomach Cancer+1 more
Bristol-Myers Squibb
Large-scale testing (Phase 3)Looking for participantsNCT06177041
What this trial is testing

M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

Who this might be right for
Locally Advanced Unresectable or Metastatic Gastric CancerLocally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
FutureGen Biopharmaceutical (Beijing) Co., Ltd 486
Large-scale testing (Phase 3)Study completedNCT05568095
What this trial is testing

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body

Who this might be right for
Advanced Upper Gastrointestinal Tract Adenocarcinoma
Arcus Biosciences, Inc. 1,040
Large-scale testing (Phase 3)Study completedNCT00020787
What this trial is testing

Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer

Who this might be right for
Esophageal CancerGastric Cancer
Jonsson Comprehensive Cancer Center 8
Large-scale testing (Phase 3)Looking for participantsNCT07385703
What this trial is testing

Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.

Who this might be right for
Adenocarcinoma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. 752
Not applicableUnknownNCT05249244
What this trial is testing

A Real World Study of the Treatment of Gastric Adenocarcinoma With Huachansu

Who this might be right for
Gastric Adenocarcinoma
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. 1,000
Testing effectiveness (Phase 2)Looking for participantsNCT03219593
What this trial is testing

Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer

Who this might be right for
Gastric CancerApatinibBiomarker
The First Affiliated Hospital of Bengbu Medical University 30
Testing effectiveness (Phase 2)Study completedNCT00719550
What this trial is testing

AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer

Who this might be right for
Esophagogastric Junction AdenocarcinomaGastric CancerEsophageal Cancer
Amgen 130
Early research (Phase 1)Not Yet RecruitingNCT07594548
What this trial is testing

Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Who this might be right for
Clinical Stage II Esophageal Adenocarcinoma AJCC v8Clinical Stage III Esophageal Adenocarcinoma AJCC v8Clinical Stage III Gastric Cancer AJCC v8+13 more
Northwestern University 18
Large-scale testing (Phase 3)Active Not RecruitingNCT05152147
What this trial is testing

Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Who this might be right for
Gastric NeoplasmsGastroesophageal AdenocarcinomaEsophageal Adenocarcinoma
Jazz Pharmaceuticals 920
Testing effectiveness (Phase 2)Study completedNCT02128243
What this trial is testing

Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer

Who this might be right for
Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal JunctionGastric NeoplasmGastroesophageal Junction Adenocarcinoma+3 more
AIO-Studien-gGmbH 242
Large-scale testing (Phase 3)Study completedNCT02625610
What this trial is testing

Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)

Who this might be right for
Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction
EMD Serono Research & Development Institute, Inc. 499
Not applicableLooking for participantsNCT06846996
What this trial is testing

Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China

Who this might be right for
HER2-positive Gastric CancerHER2-positive Gastroesophageal Junction
Daiichi Sankyo 260
Testing effectiveness (Phase 2)UnknownNCT03116555
What this trial is testing

Apatinib Plus Irinotecan as Second-line Treatment in AGC or EGJA

Who this might be right for
Metastatic Gastric Adenocarcinoma
China Medical University, China 37
Testing effectiveness (Phase 2)Study completedNCT03941873
What this trial is testing

Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer

Who this might be right for
Carcinoma, HepatocellularGastric/Gastroesophageal Junction Cancer
BeiGene 111
Early research (Phase 1)Ended earlyNCT01705340
What this trial is testing

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

Who this might be right for
Adenocarcinoma of the Gastroesophageal JunctionHER2-positive Breast CancerMale Breast Cancer+9 more
National Cancer Institute (NCI) 60
Early research (Phase 1)Ended earlyNCT02908451
What this trial is testing

AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer

Who this might be right for
Gastric CancerColorectal CancerPancreatic Cancer+1 more
AbGenomics B.V Taiwan Branch 39
Not applicableStudy completedNCT03528629
What this trial is testing

IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

Who this might be right for
Gastric CancerGastro-esophageal Junction (GEJ) Cancer
Astellas Pharma Inc 18
Testing effectiveness (Phase 2)Study completedNCT03602079
What this trial is testing

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Who this might be right for
HER2-positive Breast CancerHER2 Gene MutationHER-2 Gene Amplification+41 more
Klus Pharma Inc. 49
Next Page